ITC Requests Public Input on Remedy for Eli Lilly Section 337 Investigation
The International Trade Commission is seeking public input on remedies for its Section 337 investigation on Eli Lilly's drug tirzepatide, after declining to review the administrative law judge's initial determination finding violations, the ITC said in a notice to be…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
published Jan. 28. The ITC initially began the investigation in November 2023 based on allegations that 11 companies were importing the diabetes drug tirzepatide under Eli Lilly’s Mounjaro brand name (see 2311270054). The ALJ's initial determination granted the complainant's motion regarding trademark infringement, false designation of origin and false advertising and recommended a general exclusion order should the ITC find a violation. The ITC is requesting written submissions by close of business on Feb. 5.